Search for: "Brown v. Pfizer Inc"
Results 41 - 55
of 55
Sorted by Relevance
|
Sort by Date
15 Feb 2012, 7:42 am
Sherrod Brown, D-Ohio, would be sending a letter of recommendation for Rost as well as several other candidates for the post. [read post]
14 Sep 2011, 12:08 pm
Sherrod Brown, D-Ohio, would be sending a letter of recommendation for Rost as well as several other candidates for the post. [read post]
14 Sep 2011, 12:07 pm
Sherrod Brown, D-Ohio, would be sending a letter of recommendation for Rost as well as several other candidates for the post. [read post]
9 Sep 2011, 8:40 am
Sherrod Brown, D-Ohio, would be sending a letter of recommendation for Rost as well as several other candidates for the post. [read post]
14 Sep 2011, 12:07 pm
Sherrod Brown, D-Ohio, would be sending a letter of recommendation for Rost as well as several other candidates for the post. [read post]
14 Sep 2011, 12:08 pm
Sherrod Brown, D-Ohio, would be sending a letter of recommendation for Rost as well as several other candidates for the post. [read post]
15 Apr 2009, 4:44 am
Friends for All Children, Inc. v. [read post]
25 Jun 2009, 4:29 am
In re Amgen Inc. [read post]
8 Oct 2008, 11:50 am
Pfizer, Inc., 153 S.W.3d 758, 762 (Ky. 2004) (not a holding, but dictum suggesting broad comment k application).Louisiana: Kinney v. [read post]
15 Sep 2011, 4:06 am
See Brown v. [read post]
14 Jul 2012, 7:08 am
Philip Morris USA, Inc., 449 F. [read post]
29 Dec 2010, 12:54 pm
Wyeth, Inc. v. [read post]
22 Jun 2010, 12:41 pm
Pedreira; Brown v. [read post]
16 Aug 2009, 9:51 pm
In reliance of Black & Decker, Inc. v Robert Bosch Tool Corp (2008) Microsoft argued that the objective prong of the willfulness analysis is satisfied only if a defendant fails to present valid defences during the proceedings. [read post]
28 Apr 2008, 11:00 am
: (Patent Docs), US: Supreme Court declines to hear final Nucleonics’ appeal in gene-silencing patent dispute with Benitec Australia: (IP Law360), (Therapeutics Daily), US: 505(b)(2) drug approvals rock - Interaction of patents and exclusivity of drugs approved by FDA under section 505(b)(2): (Patent Baristas), US: StemCells’ patents survive reexam – StemCells and Neuralstem differ on extent of changes: (Patent Docs), US: StemCells announces issuance of… [read post]
